Income Statement
BOUNDLESS BIO, INC.
BOLD
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Revenue
|
- | - |
|
Cost of Revenue
|
- | - |
|
Gross Profit
|
- | - |
|
Operating Expenses
|
63.55 | 73.27 |
|
Research & Development
|
44.85 | 55.27 |
|
Selling, General & Administrative
|
18.71 | 18.00 |
|
Other Operating Expenses
|
- | - |
|
Operating Income
|
-63.55 | -73.27 |
|
Non-Operating Income
|
5.36 | 7.90 |
|
Interest Income
|
5.36 | 7.89 |
|
Interest Expense
|
- | - |
|
Other Non-Op Income / Expense
|
0.00 | 0.01 |
|
Income Before Tax
|
- | - |
|
Income Tax Expense
|
- | - |
|
Non-Controlling Interest
|
- | - |
|
Net Income
|
-58.20 | -65.36 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Depreciation & Amortization
|
- | - |
|
EBITDA
|
-62.30 | -72.18 |
|
Earnings Per Share (Basic)
|
-2.60 | -3.85 |
|
Diluted EPS
|
-2.60 | -3.85 |
|
Weighted Average Shares
|
22.36 | 16.98 |
|
Diluted Weighted Avg Shares
|
22.36 | 16.98 |
|
Comprehensive Income
|
-58.25 | -65.28 |